Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531).
Pullarkat
Vinod A
VA
Gernsheimer
Terry B
TB
Wasser
Jeffrey S
JS
Newland
Adrian
A
Guthrie
Troy H
TH
de Wolf
Joost Th M
JT
Stewart
Ron
R
Berger
Dietmar
D
D002352:Carrier Proteins / Q000008:administration & dosage*; D002908:Chronic Disease; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage*; D008297:Male; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011961:Receptors, Fc / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin
D002352:Carrier Proteins; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim